FOXO4-DRI

Identity a synthetic, engineered peptide designed as a senolytic — an agent that selectively destroys senescent cells ("zombie cells" that have stopped dividing but refuse to die, and poison surrounding tissue with inflammatory signals). It works by disrupting a specific protein-protein interaction between FOXO4 and p53. The "DRI" (D-Retro-Inverso) construction — building the peptide from D-amino acids (mirror images of natural L-amino acids) in reverse sequence — makes it resistant to protease degradation and far more stable than an ordinary peptide, while preserving the binding shape. ## Mechanism (as proposed) senescent cells are in a bind: they carry lots of damage, so they express high p53 (which should trigger apoptosis) — but they survive by using FOXO4 to bind p53 and keep it sequestered in the nucleus, blocking its pro-death program. FOXO4-DRI is a decoy: it mimics FOXO4's p53-binding region with higher affinity, so it competitively displaces the real FOXO4. Freed p53 then relocates to the mitochondria and executes apoptosis — the senescent cell finally dies (senolysis). The selectivity is the clever part: non-senescent cells barely express FOXO4 and don't maintain the chronic p53-FOXO4 complex, so FOXO4-DRI has nothing to disrupt in them — "you can't break a complex that isn't there." The D-Retro-Inverso design keeps this decoy stable in the body. Elegant and well-validated in models — but note that what it ultimately does is unleash p53, which is why systemic, chronic human use is not a trivial safety question.